食管鳞状细胞癌免疫治疗的现状与展望  

Research status and prospect of immunotherapy for esophageal squamous cell carcinoma

作　　者：何楚楚 陆海波[1] HE Chuchu;LU Haibo(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2021年第14期2566-2569,共4页Journal of Modern Oncology

摘　　要：食管鳞状细胞癌是我国食管癌患者主要的病理类型,目前针对食管鳞癌的免疫治疗显示出新的曙光。免疫抑制剂的疗效令人鼓舞,过继性T细胞疗法和肿瘤疫苗在食管鳞癌方面取得了巨大进步;溶瘤病毒也在针对食管鳞癌方面取得进展;免疫检查点抑制剂与放化疗联合治疗正在积极的试验中。肿瘤免疫治疗因其突出的有效性和安全性,为食管鳞癌患者制定个性化治疗方案提供有意义的指导。Esophageal squamous cell carcinoma is the main pathological type of esophageal cancer in China.The efficacy of immunosuppressants is encouraging.Adoptive T-cell therapy and tumor vaccines have made great progress in esophageal squamous cell carcinoma.Oncolytic viruses have also made progress against esophageal squamous cell carcinoma.Immunocheckpoint inhibitors combined with chemoradiotherapy are being actively tested.Due to its outstanding effectiveness and safety,tumor immunotherapy provides meaningful guidance for the development of personalized treatment plans for patients with esophageal squamous cell carcinoma.

关 键 词：食管鳞状细胞癌 免疫治疗 肿瘤疫苗 溶瘤病毒 联合治疗 

分 类 号：R735.1[医药卫生—肿瘤]